Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) will attend the JP Morgan Healthcare Conference in San Francisco on 12–15 January, a key global meeting point for healthcare investors and industry leaders. The company develops gene therapies targeting the SIRT6 longevity pathway and said the event offers a chance to meet prospective partners and pharmaceutical groups as it advances its lipid nanoparticle delivery work for mRNA-based treatments. Chief executive Eric Leire said the meetings planned for the conference reflect growing interest in technologies aimed at extending healthy lifespan.
The Markets by Proactive
Go to Proactive UK
Proactive’s coverage of London’s small caps continues on .com